Significant progress achieved in SB011 development programme
Marburg, Germany, 06 March 2014
Phase I trial of SB011 for the treatment of atopic dermatitis successfully completed
First patient enrolled in Phase IIa proof-of-concept trial
sterna biologicals GmbH & Co. KG (“sterna biologicals”) announced today successful completion of a Phase I study assessing the irritation potential of SB011 in healthy volunteers. SB011 is an emulsion containing 2% GATA-3-specific DNAzyme and employs sterna biologicals’ proprietary dermal delivery system which has demonstrated excellent protective and skin penetration enhancing effects in pre-clinical studies.